Radium-223 for men with hormone-refractory prostate cancer and bone metastases

被引：6
|
作者：
Shelley, Mike D. [1 ]
Mason, Malcolm D.
机构：
[1] Velindre NHS Trust, Cochrane Urol Canc Unit, Cardiff CF14 2TL, Wales
[2] Velindre NHS Trust, Dept Oncol, Cardiff CF14 2TL, Wales
来源：
LANCET ONCOLOGY | 2007年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1470-2045(07)70180-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：564 / 565
页数：2
相关论文
共 50 条
  • [41] Radium-223 dichloride treatment for prostate cancer with bone metastases: A symptomatic outcome review of 12 months experience
    Lee, H. H.
    McAddy, N. C.
    O'Sullivan, P.
    Crawley, P.
    Beesley, S.
    Naji, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S214 - S215
  • [42] Radium-223 dichloride in castration-resistant prostate cancer with symptomatic bone metastases: a guide to its use
    Shirley M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2016, 32 (3) : 98 - 103
  • [43] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Hiroji Uemura
    Hirotsugu Uemura
    Nobuaki Matsubara
    Seigo Kinuya
    Makoto Hosono
    Yoko Yajima
    Toshihiko Doi
    International Journal of Clinical Oncology, 2017, 22 : 954 - 963
  • [44] Efficacy and Safety of Radium-223 Dichloride in the Treatment of Patients with Castration-Resistant Prostate Cancer with Bone Metastases
    Sanchez Lopez, Hector
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 1 - 2
  • [45] Radium-223 and atezolizumab in platinum refractory urothelial carcinoma with bone metastases: NCT03208712.
    Yentz, Sarah Elizabeth
    Reimers, Melissa Andrea
    Daignault, Stephanie
    Piert, Morand
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [46] Treatment of patients with castration-resistant prostate cancer and bone metastases with radium-223: A single institution experience
    Devarakonda, Srinivas S.
    Skweres, Justin
    Nair, Binu Sivaraman
    Dhawan, Manish
    Takalkar, Amol
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review
    Cursano, M. C.
    Iuliani, M.
    Casadei, C.
    Stellato, M.
    Tonini, G.
    Paganelli, G.
    Santini, D.
    De Giorgi, U.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 146
  • [48] Efficacy and tolerance of radium-223 dichloride in patients treated for castration-resistant prostate cancer with bone metastases
    Awoudou, C.
    Bathily, E. H. A. L.
    Djigo, M. S.
    Ndong, B.
    Mbodj, M.
    Paulus, P.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2024, 48 (03): : 150 - 157
  • [49] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Uemura, Hiroji
    Uemura, Hirotsugu
    Matsubara, Nobuaki
    Kinuya, Seigo
    Hosono, Makoto
    Yajima, Yoko
    Doi, Toshihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (05) : 954 - 963
  • [50] The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases
    Ram, Prasanna
    Mandal, Swarnendu
    Das, Manoj K.
    Nayak, Prasant
    PROSTATE, 2023, 83 (06): : 613 - 613
12345